News | May 12, 2022
Suven Pharmaceuticals - CDMO core growth intact; formulations to pick up
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
Cipla has reported consolidated financial results for the period ended March 31, 2022
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
The partners also aim to expand their work to Latin America for the first time
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
RNA extraction free kit to deliver results in just 45 minutes
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Subscribe To Our Newsletter & Stay Updated
